Amgen AMGN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Amgen first to win EU backing for new kind of cholesterol drug

      Headlines

      Fri, 22 May 2015

      May 22 (Reuters) - Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA.

    2. BRIEF-EU Medicines Agency gives nod for Amgen's cholesterol drug

      Headlines

      Fri, 22 May 2015

      * Recommends approval of cholesterol drug Repatha from Amgen Inc

    3. Amgen cholesterol drug could get EU green light this week

      Headlines

      Tue, 19 May 2015

      LONDON, May 19 (Reuters) - Amgen 's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi.

    4. Strong ASCO Data Supports Our Above-Consensus IO Sales Projections; Merck Looks Most Undervalued

      Commentary

      Thu, 14 May 2015

      progression free survival benefit (19.4 versus 14.9 months) should be enough for approval. However, we expect limited market share gains for the drug against Amgen 's Kyprolis, which posted slightly better data in this setting.

    5. UPDATE 1-Novartis 'biosimilar' drug blocked by U.S. appeals court

      Headlines

      Thu, 7 May 2015

      May 7 (Reuters) - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

    6. Novartis AG's 'biosimilar' drug sale blocked by U.S. appeals court

      Headlines

      Thu, 7 May 2015

      May 7 (Reuters) - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen Inc's blockbuster drug used to prevent infections in cancer...

    7. Regeneron Reports Strong 1Q as Eylea Growth Benefits from DME Indication; Increasing FVE

      Commentary

      Thu, 7 May 2015

      program remains on track to launch in the third quarter (July 24 PDUFA date) following an FDA advisory committee in early June ( Amgen ’s panel for Repatha is the next day). Sarilumab will report Phase III data in rheumatoid arthritis later this year and

    8. Celgene 1Q Results In-Line, Firm Secures Even More Partnerships; Maintaining Our Fair Value Estimate

      Commentary

      Thu, 30 Apr 2015

      enjoy market share expansion as a result of the new first-line indication in the U.S. and Europe, and combination use with Amgen 's Kyprolis will likely lengthen duration of therapy even more. A decision on Revlimid's polymorph patent in Europe (2024

    9. UPDATE 1- FDA panel recommends approval for Amgen's skin cancer immunotherapy

      Headlines

      Wed, 29 Apr 2015

      April 29 (Reuters) - Amgen Inc's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug...

    10. FDA panel recommends approval for Amgen's skin cancer immunotherapy

      Headlines

      Wed, 29 Apr 2015

      April 29 (Reuters) - Amgen Inc's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug...

    « Prev12345Next »
    Content Partners